Perspective: tumour spread--the problems of latency.
Tumour latency, or dormancy, is a well-recognized clinical phenomenon and induction or maintenance of this state would appear to offer a novel therapeutic approach to limiting the effects of neoplastic disease. Current interest has focused on the role that neovascularization plays in this process and the consequences of shifts in the balance between angiogenic and anti-angiogenic peptides. Targeting tumour vasculature by the administration or induction of such anti-angiogenic peptides is close to clinical evaluation.
Hart
I R
IR
Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, Rayne Institute, St Thomas' Hospital, London, U.K. i.hart@icrf.icnet.uk
D000818:Animals; D002455:Cell Division; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000098:blood supply* / Q000276:immunology / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000628:therapy*